Volume 10 Supplement 1
407 Characterization of myocardial mby CMR
© Lindberg et al; licensee BioMed Central Ltd. 2008
Published: 22 October 2008
Eighteen y/o female with recurrent granular cell tumor excised X3 from groin over 3 year period. After 3rd recurrence, the patient and family agreed to aggressive chemotherapy regime. An echocardiogram was performed for cardiac clearance prior to treatment which showed normal systolic LV function but a thickened lateral wall with potential mass. The diagnosis of metastatic disease, hypertrophic cardiomyopathy, primary cardiac malignancy, infiltrating disease or Fabry's disease were considered.
Cardiac MRI was performed to characterize abnormalities seen on echocardiogram.
Patient was scanned in a Siemens 1.5 T Avanto scanner. All sequences were cardiac gated. Multi plane Trufisp, HASTE, STIR, TSE T1, Fat Sat were performed. After Gadolinium administration, perfusion, Phase Sensitive Inversion recovery and TSE T1 were completed.
Trufisp imaging showed normal LV function with thickened basal andterolateral and inferolateral wall. On black blood TSE the thickened area is isointense and appear to be intramyocardial. Fat suppression sequences show no saturation of the thickened area. On STIR, the thickened area was hyperintense. Perfusion imaging in four chamber and short axis views showed a well defined mass measuring 2 × 3 cm. Phase Sensitive Inversion Recovery images 15 minutes post gadolinium infusion showed heterogeneous enhancement of the mass. Also noted was an additional area of mid myocardial enhancement in the mid anterior wall. The combination of 1st pass perfusion and PSIR sequences lead to a differential diagnosis of metastatic tumor or malignant or benign primary cardiac tumor. Review of the specimen from groin site excision raised suspicion for sarcoma.
Cardiac MRI perfusion and delayed enhancement imaging is an effective noninvasive technique to characterize masses in the myocardium that may masquerade as other cardiomyopathic diseases.
This article is published under license to BioMed Central Ltd.